Summary
A summary is not available yet. Read the original reporting below.
GSK shares dive as weaker vaccine sales unnerve investors
Source excerpt
This is the available feed excerpt, which may be shortened or in the publisher’s original language.
British pharma company one of biggest fallers on FTSE 100 despite better than expected financial resultsBusiness live – latest updatesShares in GSK slid on Wednesday despite the UK drugmaker reporting better than expected financial results, as investors were unnerved by weaker sales of its respiratory syncytial virus (RSV) and shingles vaccines, and recently launched medications.Britain’s second-biggest pharmaceutical company reported a 19% decline in pre-tax profit to £1.9bn in the July to September quarter and £318m of restructuring charges, with more to come. Core operating profit and core earnings per share rose 5% and 1% respectively, however, beating analysts’ expectations. Continue reading...
About priority
An automated sorting aid based on source trust, keywords, and entities, on a scale of 1–12. High: 9–12; medium: 6–8; low: 1–5. It does not measure urgency, verify reporting, or indicate editorial endorsement.